Brokerages Set Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) PT at $37.33

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $37.3333.

NBTX has been the subject of a number of recent research reports. UBS Group increased their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Guggenheim increased their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Leerink Partners raised their target price on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th.

Nanobiotix Stock Performance

NBTX opened at $36.07 on Friday. The company has a 50-day moving average price of $37.91 and a 200 day moving average price of $29.79. Nanobiotix has a twelve month low of $4.18 and a twelve month high of $57.14.

Nanobiotix (NASDAQ:NBTX) last issued its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million for the quarter. As a group, equities analysts forecast that Nanobiotix will post 0.19 EPS for the current fiscal year.

Institutional Trading of Nanobiotix

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth $390,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the fourth quarter worth $220,000. Optiver Holding B.V. acquired a new stake in Nanobiotix during the third quarter worth $101,000. Finally, Royal Bank of Canada increased its stake in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares during the last quarter. 38.81% of the stock is owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.